Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24122
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArnold, D. L.-
dc.contributor.authorBarnett, M.-
dc.contributor.authorComi, G.-
dc.contributor.authorGiovannoni, G.-
dc.contributor.authorPelletier, D.-
dc.contributor.authorRovira, A.-
dc.contributor.authorSchippling, S.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorMargolin, D. H.-
dc.contributor.authorThangavelu, K.-
dc.contributor.authorTraboulsee, A.-
dc.date.accessioned2017-08-07T11:48:18Z-
dc.date.available2017-08-07T11:48:18Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22(S3), p. 329-329 (Art N° P683)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24122-
dc.description.sponsorshipSanofi Genzyme and Bayer HealthCare Pharmaceuticals. DLA: Compensation for serving as a speaker, consulting, and advisory board participant, and receiving research support (Acorda, Bayer, Biogen, Canadian Institutes of Health Research, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, MedImmune, Merck Serono, MS Society of Canada, NeuroRx Research, Novartis, Opexa Therapeutics, Receptos, Roche, Sanofi, Sanofi Genzyme, and Teva). GC: Consulting fees (Actelion, Bayer, Merck Serono, Novartis, Sanofi Genzyme, and Teva); lecture fees (Bayer, Biogen Dompe, Merck Serono, Novartis, Sanofi Genzyme, Serono Symposia International Foundation, and Teva). GG: Consulting and/or grant/research support (Abbvie, Bayer, Biogen, Canbex Therapeutics, Five Prime Therapeutics, GlaxoSmithKline, GW Pharma, Merck, Merck Serono, Novartis, Oxford Pharmagenesis, Protein Discovery Laboratories, Roche, Sanofi Genzyme, Synthon, Teva Neuroscience, and UCB). DP: Consulting and/or speaking fees, and grant/research support (Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Vertex). AR: Consulting and/or speaking fees (Bayer, Biogen, Bracco, Novartis, Sanofi Genzyme, and Stendhal). BVW: Research and travel grants, honoraria for MS expert advice and speaker's fees (Bayer-Schering, Biogen, Merck-Serono, Novartis, Roche, Sanofi Genzyme, and Teva). AT: Consulting and/or speaking fees, and grant/research support (Biogen, Chugai, Roche, Sanofi Genzyme, and Teva).-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleDurable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage329-
dc.identifier.issueS3-
dc.identifier.spage329-
dc.identifier.volume22-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Arnold, D. L.] NeuroRx Res, Montreal, PQ, Canada. [Arnold, D. L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Barnett, M.] Univ Sydney, Sydney, NSW, Australia. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Giovannoni, G.] Queen Mary Univ London, Barts & London Sch Med, London, England. [Pelletier, D.] Univ Southern Calif, Los Angeles, CA USA. [Rovira, A.] Vall dHebron Univ Hosp, Barcelona, Spain. [Schippling, S.] Univ Zurich Hosp, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.] Sanofi Genzyme, Cambridge, MA USA. [Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP683-
dc.identifier.isi000383267201422-
item.fulltextWith Fulltext-
item.contributorArnold, D. L.-
item.contributorBarnett, M.-
item.contributorComi, G.-
item.contributorGiovannoni, G.-
item.contributorPelletier, D.-
item.contributorRovira, A.-
item.contributorSchippling, S.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorMargolin, D. H.-
item.contributorThangavelu, K.-
item.contributorTraboulsee, A.-
item.fullcitationArnold, D. L.; Barnett, M.; Comi, G.; Giovannoni, G.; Pelletier, D.; Rovira, A.; Schippling, S.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K. & Traboulsee, A. (2016) Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study. In: MULTIPLE SCLEROSIS JOURNAL, 22(S3), p. 329-329 (Art N° P683).-
item.accessRightsRestricted Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
10.1177@1352458516663081.pdf
  Restricted Access		Published version389.97 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.